PALOMA-2: Addition of Palbociclib to Frontline Letrozole Significantly Improves PFS in Postmenopausal ER+/HER2- Advanced Breast Cancer

June 3-7, 2016; Chicago, Illinois
Palbociclib + letrozole achieved longest improvement in PFS seen to date for frontline treatment of ER+/HER2- advanced breast cancer.
Format: Microsoft PowerPoint (.ppt)
File Size: 747 KB
Released: June 14, 2016

Acknowledgements

This activity is supported by educational grants from
Amgen
Ariad Pharmaceuticals
Bayer HealthCare Pharmaceuticals Inc.
Celgene Corporation
Genentech
Incyte
Merck & Co., Inc.
Taiho Pharmaceuticals

Related Content

Dr Denise Yardley discusses key ongoing trials in HR-positive/HER2-negative early breast cancer, from Clinical Care Options (CCO)

Denise A. Yardley, MD Physicians: maximum of 0.5 AMA PRA Category 1 Credits Registered Nurses: 0.5 Nursing contact hours Pharmacists: 0.5 contact hours (0.05 CEUs) Released: September 22, 2022 Expired: September 21, 2023

Downloadable slides from Dr Denise Yardley on key ongoing trials in HR-positive/HER2-negative early breast cancer, from Clinical Care Options (CCO)

Denise A. Yardley, MD Released: September 22, 2022

Slideset from Dr Denise Yardley on immunotherapy in early TNBC, from Clinical Care Options (CCO)

Denise A. Yardley, MD
Program Director
Released: September 15, 2022

Dr Denise Yardley discusses immunotherapy in early TNBC, from Clinical Care Options (CCO)

Denise A. Yardley, MD
Program Director
Physicians: maximum of 0.5 AMA PRA Category 1 Credits Registered Nurses: 0.5 Nursing contact hours Pharmacists: 0.5 contact hours (0.05 CEUs) Released: September 15, 2022 Expired: September 14, 2023

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings